Skip to content
10-Q

Quarterly Report

Lexeo Therapeutics, Inc. LXEO

0001193125-26-215678

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 78.52M sh
Shares Diluted Q1 2026 · Mar 31, 2026 81.18M sh
Shares Diluted Q1 2026 · Mar 31, 2025 33.11M sh
Capex Q1 2026 · Mar 31, 2026 $35K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$21.14M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$21.72M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $71.77M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $63M
Stockholders Equity Q1 2026 · Mar 31, 2026 $231.5M
Stockholders Equity Q1 2026 · Dec 31, 2025 $246.67M
Stockholders Equity Q1 2026 · Mar 31, 2025 $88.12M
Stockholders Equity Q1 2026 · Dec 31, 2024 $116.84M
Current Liabilities Q1 2026 · Mar 31, 2026 $14.19M
Current Liabilities Q1 2026 · Dec 31, 2025 $16.81M
Total Liabilities Q1 2026 · Mar 31, 2026 $18.86M
Total Liabilities Q1 2026 · Dec 31, 2025 $22.02M
Current Assets Q1 2026 · Mar 31, 2026 $200.86M
Current Assets Q1 2026 · Dec 31, 2025 $188.39M
Total Assets Q1 2026 · Mar 31, 2026 $250.36M
Total Assets Q1 2026 · Dec 31, 2025 $268.69M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.25
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.99
Eps Basic Q1 2026 · Mar 31, 2026 −$0.25
Eps Basic Q1 2026 · Mar 31, 2025 −$0.99
Sga Expense Q1 2026 · Mar 31, 2026 $6.63M
Sga Expense Q1 2026 · Mar 31, 2025 $16.63M
Rd Expense Q1 2026 · Mar 31, 2026 $15.7M
Rd Expense Q1 2026 · Mar 31, 2025 $17.17M
Net Income Q1 2026 · Mar 31, 2026 −$20.2M
Net Income Q1 2026 · Dec 31, 2025 −$100M
Net Income Q1 2026 · Mar 31, 2025 −$32.66M
Operating Income Q1 2026 · Mar 31, 2026 −$22.33M
Operating Income Q1 2026 · Mar 31, 2025 −$33.81M